These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
661 related articles for article (PubMed ID: 28434150)
1. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150 [TBL] [Abstract][Full Text] [Related]
2. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034 [TBL] [Abstract][Full Text] [Related]
3. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102 [TBL] [Abstract][Full Text] [Related]
4. High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer. Mokuyasu S; Suzuki Y; Kawahara E; Seto T; Tokuda Y Breast Cancer; 2015 Nov; 22(6):563-9. PubMed ID: 24563373 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762 [TBL] [Abstract][Full Text] [Related]
6. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946 [TBL] [Abstract][Full Text] [Related]
7. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer. Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235 [TBL] [Abstract][Full Text] [Related]
8. [Early detection of the cardiotoxicity induced by chemotherapy drug through two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T]. Wang W; Kang Y; Shu XH; Shen XD; He B Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):835-840. PubMed ID: 29151290 [No Abstract] [Full Text] [Related]
9. Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab. Canale ML; Casolo G; Donati S; Bisceglia I; Puccetti C; Amoroso D; Venturini E; Maurea N; Turazza FM; Camerini A In Vivo; 2023; 37(5):2139-2146. PubMed ID: 37652487 [TBL] [Abstract][Full Text] [Related]
10. Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT. Zhang CJ; Pei XL; Song FY; Guo Y; Zhang QL; Shu XH; Hsi DH; Cheng LL Echocardiography; 2017 Nov; 34(11):1593-1600. PubMed ID: 28942608 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038 [TBL] [Abstract][Full Text] [Related]
12. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174 [TBL] [Abstract][Full Text] [Related]
13. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy. Tzolos E; Adamson PD; Hall PS; Macpherson IR; Oikonomidou O; MacLean M; Lewis SC; McVicars H; Newby DE; Mills NL; Lang NN; Henriksen PA Clin Oncol (R Coll Radiol); 2020 May; 32(5):292-297. PubMed ID: 31813662 [TBL] [Abstract][Full Text] [Related]
14. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937 [TBL] [Abstract][Full Text] [Related]
15. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab]. Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270 [TBL] [Abstract][Full Text] [Related]
16. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients. Matos E; Jug B; Blagus R; Zakotnik B Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108 [TBL] [Abstract][Full Text] [Related]
17. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment. Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992 [TBL] [Abstract][Full Text] [Related]
18. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467 [TBL] [Abstract][Full Text] [Related]
19. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Ponde N; Bradbury I; Lambertini M; Ewer M; Campbell C; Ameels H; Zardavas D; Di Cosimo S; Baselga J; Huober J; Izquierdo M; Fumagalli D; Bozovic-Spasojevic I; Maetens M; Harbeck N; Pusztai L; Berghorn M; Im YH; Borrego MR; Chen DR; Rodeheffer R; Piccart M; Suter T; de Azambuja E Breast Cancer Res Treat; 2018 Apr; 168(3):631-638. PubMed ID: 29280043 [TBL] [Abstract][Full Text] [Related]
20. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer. Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H; PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]